High mass (> 18 g) of late gadolinium enhancement on CMR imaging is associated with major cardiac events on long-term outcome in patients with biopsy-proven extracardiac sarcoidosis

Lucia Agoston-Coldea, Sylvain Kouaho, Karim Sacre, Antoine Dossier, Brigitte Escoubet, Sylvie Chillon, Jean Pierre Laissy, François Rouzet, Shelby Kutty, Fabrice Extramiana, Antoine Leenhardt, Raphael Borie, Bruno Crestani, Phalla Ou

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Background Cardiac involvement is the most important cause of mortality in patients with systemic sarcoidosis. Late gadolinium enhancement (LGE) on cardiovascular magnetic resonance imaging (CMR) has been shown to be a predictor of major cardiovascular adverse events (MACE) in the setting of systemic sarcoidosis. We sought to evaluate the relationship between LGE mass and adverse long-term outcome in patients with biopsy-proven extracardiac sarcoidosis. Methods Between 2001 and 2013, 197 consecutive patients with suspected cardiac sarcoidosis were identified in our institution database. Of them, 56 patients have had biopsy-proven extracardiac sarcoidosis and represented our studied population. Patients were divided into two groups based on LGE mass by a median value (mild LGE < 18 g, high LGE > 18 g) for comparison of MACE. Results Twenty-eight patients had a high mass of LGE. Of them, 15 (54%) experienced MACE (OR = 31.15, 95% CI 3.7–262). Except for 1 patient, no patient with mild LGE presented with any MACE during follow-up (median of 32 months). Patients with high LGE had lower CMR-derived left (53.6 ± 14.9 vs. 62.2 ± 6.7, p < 0.01) and right (49.1 ± 11.5 vs. 56.4 ± 9.2, p < 0.05) ventricular ejection fractions. LGE mass of 18 g discriminated patients with and without MACE (93% sensitivity, 88% specificity, AUC = 0.972). LGE mass was the only independent predictor of MACE on multivariate Cox analysis adjusted (OR = 1.7, 95% CI 1.06 to 2.72, p = 0.03). Conclusion In biopsy-proven extracardiac sarcoidosis patients, a high mass of LGE > 18 g was associated with MACE.

Original languageEnglish (US)
Pages (from-to)950-956
Number of pages7
JournalInternational Journal of Cardiology
Volume222
DOIs
StatePublished - Nov 1 2016

Fingerprint

Gadolinium
Sarcoidosis
Magnetic Resonance Imaging
Biopsy
Databases
Mortality

Keywords

  • Cardiac magnetic resonance imaging
  • Cardiac sarcoidosis
  • Late gadolinium enhancement

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

High mass (> 18 g) of late gadolinium enhancement on CMR imaging is associated with major cardiac events on long-term outcome in patients with biopsy-proven extracardiac sarcoidosis. / Agoston-Coldea, Lucia; Kouaho, Sylvain; Sacre, Karim; Dossier, Antoine; Escoubet, Brigitte; Chillon, Sylvie; Laissy, Jean Pierre; Rouzet, François; Kutty, Shelby; Extramiana, Fabrice; Leenhardt, Antoine; Borie, Raphael; Crestani, Bruno; Ou, Phalla.

In: International Journal of Cardiology, Vol. 222, 01.11.2016, p. 950-956.

Research output: Contribution to journalArticle

Agoston-Coldea, L, Kouaho, S, Sacre, K, Dossier, A, Escoubet, B, Chillon, S, Laissy, JP, Rouzet, F, Kutty, S, Extramiana, F, Leenhardt, A, Borie, R, Crestani, B & Ou, P 2016, 'High mass (> 18 g) of late gadolinium enhancement on CMR imaging is associated with major cardiac events on long-term outcome in patients with biopsy-proven extracardiac sarcoidosis', International Journal of Cardiology, vol. 222, pp. 950-956. https://doi.org/10.1016/j.ijcard.2016.07.233
Agoston-Coldea, Lucia ; Kouaho, Sylvain ; Sacre, Karim ; Dossier, Antoine ; Escoubet, Brigitte ; Chillon, Sylvie ; Laissy, Jean Pierre ; Rouzet, François ; Kutty, Shelby ; Extramiana, Fabrice ; Leenhardt, Antoine ; Borie, Raphael ; Crestani, Bruno ; Ou, Phalla. / High mass (> 18 g) of late gadolinium enhancement on CMR imaging is associated with major cardiac events on long-term outcome in patients with biopsy-proven extracardiac sarcoidosis. In: International Journal of Cardiology. 2016 ; Vol. 222. pp. 950-956.
@article{40f51d0a5c92413bb9ee37f3011a962a,
title = "High mass (> 18 g) of late gadolinium enhancement on CMR imaging is associated with major cardiac events on long-term outcome in patients with biopsy-proven extracardiac sarcoidosis",
abstract = "Background Cardiac involvement is the most important cause of mortality in patients with systemic sarcoidosis. Late gadolinium enhancement (LGE) on cardiovascular magnetic resonance imaging (CMR) has been shown to be a predictor of major cardiovascular adverse events (MACE) in the setting of systemic sarcoidosis. We sought to evaluate the relationship between LGE mass and adverse long-term outcome in patients with biopsy-proven extracardiac sarcoidosis. Methods Between 2001 and 2013, 197 consecutive patients with suspected cardiac sarcoidosis were identified in our institution database. Of them, 56 patients have had biopsy-proven extracardiac sarcoidosis and represented our studied population. Patients were divided into two groups based on LGE mass by a median value (mild LGE < 18 g, high LGE > 18 g) for comparison of MACE. Results Twenty-eight patients had a high mass of LGE. Of them, 15 (54{\%}) experienced MACE (OR = 31.15, 95{\%} CI 3.7–262). Except for 1 patient, no patient with mild LGE presented with any MACE during follow-up (median of 32 months). Patients with high LGE had lower CMR-derived left (53.6 ± 14.9 vs. 62.2 ± 6.7, p < 0.01) and right (49.1 ± 11.5 vs. 56.4 ± 9.2, p < 0.05) ventricular ejection fractions. LGE mass of 18 g discriminated patients with and without MACE (93{\%} sensitivity, 88{\%} specificity, AUC = 0.972). LGE mass was the only independent predictor of MACE on multivariate Cox analysis adjusted (OR = 1.7, 95{\%} CI 1.06 to 2.72, p = 0.03). Conclusion In biopsy-proven extracardiac sarcoidosis patients, a high mass of LGE > 18 g was associated with MACE.",
keywords = "Cardiac magnetic resonance imaging, Cardiac sarcoidosis, Late gadolinium enhancement",
author = "Lucia Agoston-Coldea and Sylvain Kouaho and Karim Sacre and Antoine Dossier and Brigitte Escoubet and Sylvie Chillon and Laissy, {Jean Pierre} and Fran{\cc}ois Rouzet and Shelby Kutty and Fabrice Extramiana and Antoine Leenhardt and Raphael Borie and Bruno Crestani and Phalla Ou",
year = "2016",
month = "11",
day = "1",
doi = "10.1016/j.ijcard.2016.07.233",
language = "English (US)",
volume = "222",
pages = "950--956",
journal = "International Journal of Cardiology",
issn = "0167-5273",
publisher = "Elsevier Ireland Ltd",

}

TY - JOUR

T1 - High mass (> 18 g) of late gadolinium enhancement on CMR imaging is associated with major cardiac events on long-term outcome in patients with biopsy-proven extracardiac sarcoidosis

AU - Agoston-Coldea, Lucia

AU - Kouaho, Sylvain

AU - Sacre, Karim

AU - Dossier, Antoine

AU - Escoubet, Brigitte

AU - Chillon, Sylvie

AU - Laissy, Jean Pierre

AU - Rouzet, François

AU - Kutty, Shelby

AU - Extramiana, Fabrice

AU - Leenhardt, Antoine

AU - Borie, Raphael

AU - Crestani, Bruno

AU - Ou, Phalla

PY - 2016/11/1

Y1 - 2016/11/1

N2 - Background Cardiac involvement is the most important cause of mortality in patients with systemic sarcoidosis. Late gadolinium enhancement (LGE) on cardiovascular magnetic resonance imaging (CMR) has been shown to be a predictor of major cardiovascular adverse events (MACE) in the setting of systemic sarcoidosis. We sought to evaluate the relationship between LGE mass and adverse long-term outcome in patients with biopsy-proven extracardiac sarcoidosis. Methods Between 2001 and 2013, 197 consecutive patients with suspected cardiac sarcoidosis were identified in our institution database. Of them, 56 patients have had biopsy-proven extracardiac sarcoidosis and represented our studied population. Patients were divided into two groups based on LGE mass by a median value (mild LGE < 18 g, high LGE > 18 g) for comparison of MACE. Results Twenty-eight patients had a high mass of LGE. Of them, 15 (54%) experienced MACE (OR = 31.15, 95% CI 3.7–262). Except for 1 patient, no patient with mild LGE presented with any MACE during follow-up (median of 32 months). Patients with high LGE had lower CMR-derived left (53.6 ± 14.9 vs. 62.2 ± 6.7, p < 0.01) and right (49.1 ± 11.5 vs. 56.4 ± 9.2, p < 0.05) ventricular ejection fractions. LGE mass of 18 g discriminated patients with and without MACE (93% sensitivity, 88% specificity, AUC = 0.972). LGE mass was the only independent predictor of MACE on multivariate Cox analysis adjusted (OR = 1.7, 95% CI 1.06 to 2.72, p = 0.03). Conclusion In biopsy-proven extracardiac sarcoidosis patients, a high mass of LGE > 18 g was associated with MACE.

AB - Background Cardiac involvement is the most important cause of mortality in patients with systemic sarcoidosis. Late gadolinium enhancement (LGE) on cardiovascular magnetic resonance imaging (CMR) has been shown to be a predictor of major cardiovascular adverse events (MACE) in the setting of systemic sarcoidosis. We sought to evaluate the relationship between LGE mass and adverse long-term outcome in patients with biopsy-proven extracardiac sarcoidosis. Methods Between 2001 and 2013, 197 consecutive patients with suspected cardiac sarcoidosis were identified in our institution database. Of them, 56 patients have had biopsy-proven extracardiac sarcoidosis and represented our studied population. Patients were divided into two groups based on LGE mass by a median value (mild LGE < 18 g, high LGE > 18 g) for comparison of MACE. Results Twenty-eight patients had a high mass of LGE. Of them, 15 (54%) experienced MACE (OR = 31.15, 95% CI 3.7–262). Except for 1 patient, no patient with mild LGE presented with any MACE during follow-up (median of 32 months). Patients with high LGE had lower CMR-derived left (53.6 ± 14.9 vs. 62.2 ± 6.7, p < 0.01) and right (49.1 ± 11.5 vs. 56.4 ± 9.2, p < 0.05) ventricular ejection fractions. LGE mass of 18 g discriminated patients with and without MACE (93% sensitivity, 88% specificity, AUC = 0.972). LGE mass was the only independent predictor of MACE on multivariate Cox analysis adjusted (OR = 1.7, 95% CI 1.06 to 2.72, p = 0.03). Conclusion In biopsy-proven extracardiac sarcoidosis patients, a high mass of LGE > 18 g was associated with MACE.

KW - Cardiac magnetic resonance imaging

KW - Cardiac sarcoidosis

KW - Late gadolinium enhancement

UR - http://www.scopus.com/inward/record.url?scp=84981333360&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84981333360&partnerID=8YFLogxK

U2 - 10.1016/j.ijcard.2016.07.233

DO - 10.1016/j.ijcard.2016.07.233

M3 - Article

C2 - 27526366

AN - SCOPUS:84981333360

VL - 222

SP - 950

EP - 956

JO - International Journal of Cardiology

JF - International Journal of Cardiology

SN - 0167-5273

ER -